Telbivudine Renoprotective Effect in Patients With HBV-related Liver Cirrhosis

• To estimate renoprotective efficacy of Telbivudine treated patients with HBV-related liver cirrhosis.

Inclusion Criteria:

Subjects eligible for enrolment in the study must meet all of the following criteria:

• Aged between 18-75 years (inclusive).
• Male or female.
• Subjects with positive HBsAg for more than 6 months and anti-HBs negative regardless of HBeAg status , HBV DNA ≥2×103 IU/ml
• Subjects with HBV-related liver cirrhosis, including compensated cirrhosis and decompensated, but only Child-Pugh A or B.
• The ablility to understand and sign a written informed consent prior to any study related procedure and comply with the requirements of the study.

Exclusion Criteria:

• Subjects meeting any of the following criteria must not be enrolled in the study

  • Subjects with non-HBV cirrhosis
  • Co-infection with HAV/HCV/HDV/ HIV
  • Subjects who take nucleosides within 6 months
  • Kidney injury due to non-HBV factors
  • Inability to comply with study requirements as determined by the study investigator
  • Patients with very low GFR, who may need dialysis or renal transplantation